Botanix Pharmaceuticals Limited (ASX:BOT)
Australia
· Delayed Price · Currency is AUD 0.0540
-0.0030 (-5.26%)
Mar 9, 2026, 4:11 PM AEST
Botanix Pharmaceuticals Company Description
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States.
The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older.
Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis.
The company was incorporated in 1984 and is based in West Perth, Australia.
Botanix Pharmaceuticals Limited
| Country | Australia |
| Founded | 1984 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Howie McKibbon |
Contact Details
Address: 41-47 Colin Street West Perth, Washington 6005 Australia | |
| Phone | 61 8 6555 2945 |
| Website | botanixpharma.com |
Stock Details
| Ticker Symbol | BOT |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000BOT2 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Howie McKibbon | Chief Executive Officer |
| Vincent P. Ippolito | MD and Executive Chairman |
| Graeme Morissey | Chief Financial Officer |
| Chris Lesovitz | Chief Financial Officer of United States of America |
| Dr. Boris Meyerson Ph.D. | Chief Business Officer |
| David Morgan | Head of Corporate Affairs |
| Kevin Wojciechowski | Head of HCP Marketing and Sales Training |
| Andrew Bickley | Joint Company Secretary |
| Darin Van Arsdale | Director of Sales Operations |